Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF) Research

Kubota Pharmaceutical Holdings Co., Ltd. operates globally, concentrating on the development of innovative drugs and medical devices within the ophthalmology sector. A key asset in its product pipeline is emixustat hydrochloride, which is currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. The company is also advancing a remote, patient self-monitoring optical coherence tomography (OCT) device designed for home use, intended to address conditions like wet age-related macular degeneration and diabetic macular edema, which are characterized by retinal swelling and reduced visual acuity. Furthermore, it is developing a wearable device aimed at controlling myopia. This Tokyo, Japan-based company was founded in 2002.

Market snapshot

Symbol
KBBTF
Price
$0.96
Day change
0.00%
Market cap
$24.1M
52-week range
0.96-2.81
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Chill Brands Group PLC (CHBRF)
  • OKYO Pharma Limited (EMMLF)
  • Generation Hemp, Inc. (GENH)
  • HS GovTech Solutions Inc. (HDSLF)
  • ImmuPharma plc (IMMPF)
  • Kadimastem Ltd (KMSTF)
  • Mauna Kea Technologies S.A. (MKEAF)
  • PharmChem, Inc. (PCHM)

Open Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.